浸入科技 IMMR 深 滬
等待開盤 10-10 09:30:00 美东时间
7.06
-0.130
-1.81%
華盛通- 最 高7.19
- 今 開7.19
- 成交量 39.58万股
- 最 低 6.978
- 昨 收 7.19
- 總市值 2.29亿
- 52周最高 10.385
- 市盈率 靜 6.76
- 換手率 1.22%
- 52周最低 6.38
- 委 比 -48.53%
- 總股本 3239.64万
- 歷史最高 16.97
- 量 比 0.86
- 振 幅 2.95%
- 歷史最低 3.415
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immersion Corporation receives Nasdaq notice for delayed filing
Immersion Corporation (NASDAQ:IMMR) received a Nasdaq delinquency notice for failing to timely file its report for the quarter ended July 31, 2025. The company is now non-compliant with Nasdaq’s conti...
10-03 04:15
Immersion Corp Recevies Delinquency Compliance Notice From Nasdaq
Immersion Corporation ("Immersion", the "Company", "we", "us" or "our") (NASDAQ:IMMR), a leading provider of technologies for haptics, announced that on September 29, 2025, it received a delinquency compliance alert
10-03 04:08
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Corporation announced a proposed underwritten public offering of its Class A common stock or pre-funded warrants, alongside a private placement with Sanofi for $25 million. Proceeds will fund the advancement of preclinical and clinical development of product candidates and general corporate purposes. Leerink Partners and Oppenheimer & Co. Inc. are acting as joint bookrunners and placement agents. The offering is subject to market cond...
09-24 20:05
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
<p>Immuneering Corporation announced the appointment of Thomas J. Schall, Ph.D., as Chairman of its Board of Directors. Dr. Schall, a seasoned biotech executive and scientist with over 30 years of experience, is known for founding ChemoCentryx and leading the development of Tavneos, which was approved by the FDA and led to the company's acquisition by Amgen for nearly $4 billion. His expertise is expected to strengthen Immuneering's progress in a...
09-16 11:00
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
<p>Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, during an investor call at 8 a.m. ET. The company will also present this data at the PanCAN Scientific Summit on September 28 and review preclinical data on Deep Cyclic Inhibitors at the RAS-Targeted Drug Development Summit on September 17. Ben Zeskind, CEO, highlighted the si...
09-10 11:00
Immersion Corp. Board Declares Prior Quarterly Financial Statements For 2024-2025 Non-Reliable Due To Barnes & Noble Education Sales And Cost Accounting Issues
On September 8, 2025, the Board of Directors (the "Board") of Immersion Corporation (the "Company") concluded that the Company's previously-issued unaudited interim condensed consolidated financial statements for the
09-09 20:57
Immuneering Announces Closing of $25 Million Private Placement
<p>Immuneering Corporation announced the closing of a $25 million private placement to institutional and accredited investors. Proceeds will support the development of its cancer treatments, including a Phase 2a trial for its lead candidate, atebimetinib. Leerink Partners acted as financial advisor.</p>
08-26 20:05
Immersion Faces Nasdaq Filing Compliance Deadline
The latest update is out from Immersion ( ($IMMR) ). On August 20, 2025, Immers...
08-23 04:48
Immersion Corporation receives delinquency compliance alert notice from Nasdaq
Immersion Corporation (NASDAQ:IMMR) has received a delinquency compliance alert notice from Nasdaq notifying the company that due to the its failure to timely file its annual report on Form 10-K for t...
08-23 04:07
Immersion Announces Quarterly Cash Dividend Declaration
Immersion ( ($IMMR) ) has provided an announcement. On July 8, 2025, Immersion ...
07-09 04:56
